Aromatic Heterocyclic CDK7 Inhibitors With Selective Kinase Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The high sequence and structural similarity of kinase domains in the cyclin-dependent kinase (CDK) family hinders the development of selective CDK7 inhibitors, which are needed for treating cancers like CLL.
Innovation Solution
Development of an aromatic heterocyclic compound with a novel structure, as shown in formula I, and its stereoisomers, diastereomers, or pharmaceutically acceptable salts, which exhibit good CDK7 inhibitory activity and selectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CDK inhibitors are developed using traditional approaches, then general CDK inhibition activity can be achieved, but selectivity for CDK7 cannot be obtained due to high sequence and structural similarity of kinase domains in the CDK family
Solution Approach 1:
The patent applies local quality by introducing specific heterocyclic ring structures at particular positions of the inhibitor molecule. The compound features a pyrimidine or pyridine ring connected to specific heterocyclic groups (such as oxadiazole, thiadiazole, triazole rings) at defined positions, creating localized structural differences that enable selective binding to CDK7's unique structural features despite overall similarity across CDK family members.
Solution Approach 2:
The patent employs composite material principles by combining multiple heterocyclic rings into a single inhibitor molecule. The compound consists of a core pyrimidine or pyridine ring composite with additional heterocyclic substituents (oxadiazole, thiadiazole, triazole rings), creating a complex multi-component structure that achieves both CDK7 selectivity and inhibitory activity through synergistic interactions.
2Reliability
If CDK7 inhibitory activity is enhanced through structure optimization, then antiproliferative effect is improved, but the complexity of achieving both activity and selectivity increases
Solution Approach 1:
The patent applies parameter changes by systematically varying the heterocyclic ring substituents at different positions of the core structure. The compound explores different heterocyclic groups (oxadiazole, thiadiazole, triazole rings) with varying electronic properties, sizes, and hydrogen bonding capabilities, optimizing these structural parameters to achieve both high CDK7 inhibitory activity and selectivity while managing molecular complexity.
Data Source
AI summary
An aromatic heterocyclic compound, a pharmaceutical composition and use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer thereof, a diastereomer thereof, or a pharmaceutically acceptable salt of any one of the foregoing, or a crystal form or solvate of any one of the foregoing. The aromatic heterocyclic compound has a novel structure, good CDK7 inhibitory activity, and good selectivity.